Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06584747 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Study of Cerebral Vascular Reserve Using Pharmacological Testing With Acetazolamide: A Non-Inferiority Study of PET Method Compared to Conventional Reference Scintigraphy

Study acronym: DIAMOX-TEP
StatusActive, Not Recruiting
PhaseNot applicable
Started
View on ClinicalTrials.gov ↗

Record History

  1. Trial status: Not Yet Recruiting to Active, Not Recruitingv2 Show 4 more changesShow less
    • Enrollment target: estimated 22 to confirmed 19
    • Primary and study completion dates: Oct 2026 to Apr 9, 2027
    • Start date changed from estimate of Oct 2024 to Jan 9, 2025
    • Site contact updated
  2. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
This study compares two methods for assessing brain blood flow. PET scan will be use with a drug called Acetazolamide and compare its effectiveness to the standard scintigraphy method. The goal is to see if the PET scan is just as good as the traditional method in measuring how well the brain's blood vessels respond to the drug.
Trial Details
NCT Number NCT06584747
Lead Sponsor Centre Antoine Lacassagne
Conditions
(from sponsor)		 Cerebrovascular Circulation
Enrollment 19 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov